Within a year, Israeli scientists promise to launch a new treatment called MuTaTo that will cure cancer.

The promise has been made by the Israeli firm Accelerated Evolution Biotechnologies Ltd. (AEBi), as first reported by the Jerusalem Post and re-reported by other mainstream media outlets such as the New York Post, Forbes and the Christian Media News (CBN)

The new technology, developed by Dr. Ilan Morad is radically different from other trials to achieve an effective cure for cancer in any of its manifestations.

The treatment uses a combination of cancer peptides and a toxin that will specifically kill cancer cells.

Previous antibody-based therapies only partially attacked the cancer cells and the curative effects gave way to the development of new cells, formed from the vestiges of those already attacked, or by the mutation of malignant cells that exceed the effects of treatment. It is no coincidence that cancer, whether treated or not, has become the second “natural” cause of death.

MuTaTo, short for Multiple Target Toxin, not only targets very specific cells radically, but its multiple attacks have a faster effect than the ability of malignant cells to mutate and become resistant to treatment.

In addition to the precision of the toxin attack, the application also destroys of the malignant cell to the point where – there are no traces left that can regenerate later and mutate into new treatment-resistant cells.

MuTaTo can also be adapted to each patient. With the correct biopsy, specialized physicians can design a customized “cocktail” for each type of cancer.

Another major benefit of the new treatment would be the dramatic reduction of the side effects of the treatment on patients, since the body’s healthy cells would not be affected, as is the case with treatments applied until now where the patient’s general state of health is affected.

Because the development of peptides is easier and cheaper, MuTaTo is expected to become an effective alternative for a greater part of the population affected by a variety of cancers. For now, tests with mice in laboratories have been successful and it is estimated that within a year the application in humans will be developed.